abstract |
The present invention provides (hetero)arylcyclopropylamine compounds as LSD1 inhibitors. The present invention relates to (hetero)arylcyclopropylamine compounds, especially including compounds of formula I as described and defined herein, and their use in therapy, including, for example, in the treatment or prevention of cancer, neurological diseases or disorders, or viral infections use. |